ADC Combination Therapy for Lymphoma Was Approved

1
ADC Combination Therapy for Lymphoma
www.creative-biolabs.com/adc
2
Background
Lymphoma is a cancer that develops in the
lymphatic system and is mainly divided into two
types of Hodgkin's lymphoma and non-Hodgkin's
lymphoma. And there are large, abnormal
lymphocytes, Reed-Sternberg cells, in their lymph
nodes of most patients with Hodgkin's lymphoma.
As long as the intervention is early enough,
these patients can often achieve long-term relief.
3
ADC Combination Therapy
Recently, the FDA announced the approval of the
antibody drug conjugate of Seattle Genetics,
Adcetris (brentuximab vedotin), to expand
indications and use it together with chemotherapy
to treat patients with classic stage III or IV
classical Hodgkin's lymphoma. The approved
Adcetris is such a new drug that is expected to
bring a gospel to lymphoma patients. As an
antibody drug conjugate, it is composed of an
antibody brentuximab that targets the CD30
antigen and an anti-mitotic drug monomethyl
astasemidine E (MMAE). The CD30 protein is a
known molecular marker of classical Hodgkin's
lymphoma, and MMAE can effectively block cell
mitosis by inhibiting the polymerization of
tubulin, which consists of the conjugated
protease-cleavable agent of Seattle Genetics.
Adcetris can stably exist in the blood
circulation. When it is internalized by CD30
tumor cells, it can release MMAE, leading to cell
death.
4
The clinical trial
In a clinical trial, the potential of Adcetris to
treat classical Hodgkin's lymphoma was verified -
the researchers recruited 1,334 treated patients
who had previously received an average of 6
cycles of 28 days. Subsequently, they were
divided into two groups, one group receiving
Adcetris and chemotherapy (AVD), and the other
group receiving only chemotherapy (ABVD). Studies
have shown that compared with patients who
receive only chemotherapy, patients who receive
combination therapy experience a 23 reduction in
disease progression, death, or the need to start
new treatments. In combination with G-CSF (a
growth factor that promotes bone marrow leukocyte
growth), the combination of Adcetris and
chemotherapy is recommended by the FDA for
first-line treatment of stage III or IV classical
Hodgkin's lymphoma. In response to this
indication, Adcetris was also qualified for
breakthrough therapy and prioritized review.
5
Established in 2004, Creative Biolabs is highly
specialized in advanced antibody biochemistry and
engineering. With more than a decade of
exploration and expansion, our current research
and service capacity covers the entire new drug
discovery and development pipeline, ranging from
early discovery, pre-clinical evaluations, cGMP
manufacturing, to clinical trials. As an
international cooperation, we have established
offices all around the globe with more than 200
well-trained full-time scientists and
technicians, who work closely with our customers
and research partners to develop new medicines
for a better, healthier world. After years of
pursuit for perfection, Creative Biolabs has
established our leadership in targeted
immunotherapy and ADC development.
Creative Biolabs
6
As a global company, we have more than 200
talented and well-trained scientists located in
different continents working closely with
partners from the entire world to develop and
produce medicines of tomorrow. Specifically, we
are the established leading expert in TCR and CAR
TNK cell immune therapy development, as we offer
the one-stop custom services that cover the
entire new drug development pipeline.
Creative Biolabs
7
Contact Us
45-1 Ramsey Road, Shirley, NY 11967, USA
Email marketing_at_creative-biolabs.com
8
???? ????